Centaurus Biopharma Co., Ltd.

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Lianyungang Runzhong Pharmaceutical Co., Ltd.

Xilinx, Inc.

University of Science and Technology Beijing

Centaurus Biophrama Co., Ltd.

Yuliang Li

Hong Luo

Yongxin Han

Yong Peng

Yuandong Hu

Dengming Xiao

Hui Zhang

Li Zhu

Yinghui Sun

Na Zhao

Fansheng Kong

Ling Yang

Hongjiang Xu

Yan Zhu

Xijie Liu

Shanchun Wang

Shulong Wang

Huting Wang

Bo Liu

Zhe Wang

Xiquan Zhang

He Wang

Liguang Dai

Xiaowei Duan

Xinhe Xu

Rong Yu

Jijun Li

Zanping Wang

Wei Hu

Wei Wu

Zhihua Liu

Yu Shen

Qiong Wu

Xin Tian

Xiaoming Sun

Aiming Zhang

Dawei Zhang

Yi Shan

Yanqing Yang

Zhi Liang

Xiaogang Li

Honghao Yu

Ying Sun

Lingzhi Sui

Meng Guo

Song Yao

Chuanyu Zhang

Chaofang Dong

Xuequn Cheng

Yuanyuan Huang

Xianxing Shang

Quan Hu

Ruiyu Zhao

Mei Liu

Zhaobai Zhong

Yangjian Liu

Kuncheng Chen

Xiaofeng Zhai

Jian Sun

Yongheng Wei

Shousong Cao

The present disclosure provides a high-flux sensor suitable for corrosion big data monitoring and a method of manufacturing the same. The sensor includes a first metal sheet, a second metal sheet and an insulating sheet therebetween. The two metal sheets are laminated. The metal sheets and the insulating sheet form a test piece group. A through hole is drilled in the test piece group.

High-flux sensor suitable for corrosion big data monitoring and manufacturing method

Provided is an amino pyrazolopyrimidine compound as represented by the following structural formula used as a neurotrophic factor tyrosine kinase receptor inhibitor. The compound can inhibit the activity of Trk kinase and can treat diseases mediated by a Trk tyrosine kinase receptor in mammals. 

Amino pyrazolopyrimidine compound used as neurotrophic factor tyrosine kinase receptor inhibitor

Disclosed are compounds having formulae I and II or pharmaceutically acceptable salts or hydrates thereof, a preparation method thereof and pharmaceutical compositions thereof. The compounds having formulae I and II possesses an isocitrate dehydrogenase 2 (IDH2) inhibitory activity and are capable of treating IDH2 mutation-induced cancers. 

1,3,5-triazine derivative and method of using same

The disclosure provides a compilation method and system for heterogeneous computing platform, and a runtime method and system for supporting program execution on the heterogeneous computing platform. Inputting a trained neural network model to a Neural Network (NN) optimizing compiler to generate an NN assembly file corresponding to the neural network; inputting the NN assembly file to an NN assembler to generate an NN binary file corresponding to the neural network; compilation and assembling a neural network application developed by users in a high-level language using a host compiler toolchain to generate a corresponding host assembly file and a host binary file in sequence; and linking the NN binary file and the host binary file using a host linker to generate a single hybrid linking executable file. The technical solution of the present disclosure has the advantages such as good computing performance, strong scalability, strong compatibility and high flexibility.

Programming model of neural network-oriented heterogeneous computing platform

A pyrrolopyrimidine comprising a cyclopentyi substituent. The present invention specifically relates to a compound represented by formula. A and a stereoisomer and pharmaceutically acceptable salt thereof. The invention further relates to a method for manufacturing the pyrrolopyrimidine comprising the cyclopentyl substituent represented by formula A, a pharmaceutical composition, and an application of the compound in treating a disease induced by Janus kinase. 

Pyrrolopyrimidine comprising cyclopentyl substituent

The present invention belongs to the field of pharmaceutical chemistry, and relates to a substituted pyrrolopyrimidine CDK inhibitor, in particular to a compound as shown in formula I or a pharmaceutically acceptable salt or solvate thereof, as well as a preparation method thereof and a pharmaceutical composition thereof. The present invention also relates to the use of the compound and the pharmaceutical composition thereof in the preparation of a drug for treating diseases associated with CDK inhibition. The compound according to the present invention has a marked inhibitory effect on CDK, excellent drug absorption and significantly superior oral absorption effect. 

Substituted pyrrolopyrimidine CDK inhibitor, pharmaceutical composition containing same and use thereof

The present application relates to the field of pharmaceutical chemistry, and in particular, to a pyrrolopyrimidine compound represented by general formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof. The present invention further relates to a method for preparing the pyrrolopyrimidine compound represented by general formula (I), pharmaceutical compositions and an application of the pyrrolopyrimidine compound in treating diseases mediated by Janus Kinase. 

Pyrrolopyrimidine compound

The present disclosure relates to aniline pyrimidine derivatives or pharmaceutically acceptable salts thereof as EGFR inhibitors, specifically relates to compounds represented by formula (I) or pharmaceutically acceptable salts, pharmaceutical compositions, the method and uses thereof for treating EGFR mediated diseases. 

N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(3-methyl-2-OXO-2,3-dihydro-1h-benzo[d]imidazol-1-yl)pyrimidin-2-yl)amino)phenyl)acrylamide hydrochloride as an inhibitor of epidermal growth factor receptor activity

The present application relates to compounds represented by general formula (I), general formula (II) or general formula (III), and pharmaceutically acceptable salts or hydrates thereof, preparation methods thereof, and pharmaceutical compositions thereof. The compounds represented by general formula (I), general formula (II) or general formula (III) have inhibitory activities against isocitrate dehydrogenase 2 (IDH2), thereby being capable of treating IDH2 mutation-induced cancers. 

Antitumor compound targeting IDH2 mutation and method of use thereof

The present application relates to a substituted amino six-membered saturated heteroalicycle represented by formula I as a long-acting DPP-IV inhibitor, a method for preparing the same, a pharmaceutical composition comprising the same, and a use of the same in treating and/or preventing diseases and disorders benefitting from DPP-IV inhibition. 

Substituted amino six-membered saturated heteroalicycles as long-acting DPP-IV inhibitors

Provided are a compound represented by formula (III) or pharmaceutically acceptable salts, solvates, active metabolites, polymorphs, esters, tautomers or prodrugs thereof, pharmaceutical compositions containing the compound represented by formula (III), and the application of the pharmaceutical compositions as selective inreversible inhibitor of Bruton's tyrosine kinase for the prevention and treatment of inflammation, autoimmune diseases (such as rheumatoid arthritis) associated with aberrant B cell proliferation and cancers. 

Inhibitor of bruton's tyrosine kinase

The invention provides novel poly-substituted 5-membered heterocyclic compounds represented by Formula (IV), or a pharmaceutically acceptable salt, solvate, metabolite, polymorph, ester, tautomer or prodrug thereof, and a composition comprising these compounds. The compounds provided can be used as selective irreversible bruton's tyrosine kinase (Btk) inhibitors and are further useful to treat inflammatory, auto immune diseases associated with aberrant B-cell proliferation such as RA (rheumatoid arthritis) and cancers. This invention also provides the preparation of a medicament using of Formula (IV), and methods of preventing or treating diseases associated with excessive Btk activity in mammals, especially humans. 

Inhibitors of bruton's tyrosine kinase

The present invention relates to a quinazoline derivative shown in formula (I) and a preparation method therefor, a pharmaceutical composition comprising the compound shown in formula (I), and an application of the compound in preparing drugs for curing and preventing tumors. The compound of the present invention can irreversibly prevent EGFR phosphorylation, and effectively depress signal transduction of cancer cells, and accordingly has higher anti-tumor activity in vitro and in vivo. 

Quinazoline derivative and preparation method therefor

The present invention discloses substituted 2-aminopyridine derivatives as protein kinase inhibitors; specifically, the invention relates to 2-aminopyridine derivatives having protein kinase inhibitory properties, their manufacture, pharmaceutical compositions containing them, and use of the compounds and the pharmaceutical compositions thereof for the treatment of diseases associated with protein kinase.

Substituted 2-aminopyridine protein kinase inhibitor

The invention provides a compound represented by formula (I) which may modulate a kinase, and a pharmaceutical composition thereof, as well as the method for preventing or treating a protein kinase mediated disease or condition. 

Kinase modulating compounds, compositions containing the same and use thereof

Growing community of inventors

Beijing, China

Hong Luo